Navigation

Breast cancer - gemcitabine

Gemcitabine for the treatment of metastatic breast cancer

Status: History
Expected date of issue: January 2007
Process: STA
Topic area:
 

NICE project team

Executive Lead: Andrea Sutcliffe
Technical Lead: Ebenezer Tetteh
Communications manager: TBC
Project manager: Alana Miller
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC)
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 18 May 2006
1st appraisal committee meeting: 23 August 2006
2nd appraisal committee meeting 25 October 2006
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)
Manufacturers / Sponsors
  • Eli Lilly & Co Ltd (gemcitabine)
Patient / Carer Groups
  • Breakthrough Breast Cancer
  • Breast Cancer Campaign
  • Breast Cancer Care
  • CancerBACUP
Professional Groups
  • Association of Cancer Physicians
  • British Association of Surgical Oncology
  • British Oncology Pharmacy Association (BOPA)
  • Cancer Networks Pharmacits Forum
  • Cancer Research UK
  • Royal College of Pathologists
  • Royal College of Physicians' Medical Oncology Joint Special Committee
  • Royal College of Radiologists
Others
  • Coventry PCT
  • Department of Health
  • Welsh Assembly Government

 

General
  • British National Formulary
  • NHS Quality Improvement Scotland
Comparator Manufacturers
  • Bristol-Myers Squibb Pharmaceuticals Ltd
  • Pierre Fabre Ltd
  • Roche Products Ltd
  • Sanofi-Aventis
Evidence Review Groups
  • National Coordinating Centre for Health Technology Assessment
  • Southampton Health Technology Assessment Centre
Associated Guideline Groups
  • National Collaborating Centre for Cancer
Associated Public Health Groups
  • none
Research Groups
  • Institute of Cancer Research
  • National Cancer Research Institute

 

Top


 

Project history

Date Summary
14 March 2006 Consultees and commentators added.
30 May 2006 Project team updated.
16 June 2006 Provisional schedule and stakeholders updated.
25 July 2006 Stakeholders updated.
3 August 2006 Title changed to 'Gemcitabine for the treatment of metastatic breast cancer' to reflect the scope of the appraisal .
14 August 2006 Stakeholders updated.
5 September 2006 Stakeholders updated.
13 October 2006 Schedule updated.
23 October 2006 Schedule and project team updated.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.